AgeX Therapeutics, Inc. (AGE)
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States.
The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart.
Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases.
In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions.
AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; a collaboration with Sernova Corp.; and a research collaboration with The Ohio State University using AgeX's brown adipocyte tissue cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health, and cardiac function.
The company was founded in 2017 and is based in Alameda, California.
|IPO Date||Nov 29, 2018|
965 Atlantic Ave Ste 101
Alameda, California 94501-1079
|Phone||510 671 8370|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Dr. Michael D. West||Founder, President, Chief Executive Officer and Director|
|Eun-Jae Park CPA||Chief Financial Officer|
|Dr. Nafees Naseer Malik M.D.||Chief Operating Officer|
|Dr. Ivan Labat||Chief Information Officer|